CZ32795A3 - 4-amino-1-piperidylbenzoylguanidines, their use, process of their preparation, pharmaceutical compositions based thereon and process for preparing thereof - Google Patents

4-amino-1-piperidylbenzoylguanidines, their use, process of their preparation, pharmaceutical compositions based thereon and process for preparing thereof

Info

Publication number
CZ32795A3
CZ32795A3 CZ95327A CZ32795A CZ32795A3 CZ 32795 A3 CZ32795 A3 CZ 32795A3 CZ 95327 A CZ95327 A CZ 95327A CZ 32795 A CZ32795 A CZ 32795A CZ 32795 A3 CZ32795 A3 CZ 32795A3
Authority
CZ
Czechia
Prior art keywords
amino
alk
hal
opt
alkylene
Prior art date
Application number
CZ95327A
Other languages
English (en)
Other versions
CZ286681B6 (en
Inventor
Rolf Dr Gericke
Manfred Dr Baumgarth
Dieter Dr Dorsch
Klaus-Otto Dr Minck
Ingeborg Dr Lues
Norbert Dr Beier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CZ32795A3 publication Critical patent/CZ32795A3/cs
Publication of CZ286681B6 publication Critical patent/CZ286681B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
CZ1995327A 1994-02-10 1995-02-08 N-diaminomethylene-4-(4-aminopiperidino)-5-methylsulfonylbenzamide derivatives, their use for preparing medicaments and pharmaceutical preparation based thereon CZ286681B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4404183A DE4404183A1 (de) 1994-02-10 1994-02-10 4-Amino-1-piperidylbenzoylguanidine

Publications (2)

Publication Number Publication Date
CZ32795A3 true CZ32795A3 (en) 1995-10-18
CZ286681B6 CZ286681B6 (en) 2000-06-14

Family

ID=6509922

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ1995327A CZ286681B6 (en) 1994-02-10 1995-02-08 N-diaminomethylene-4-(4-aminopiperidino)-5-methylsulfonylbenzamide derivatives, their use for preparing medicaments and pharmaceutical preparation based thereon

Country Status (22)

Country Link
US (1) US5461066A (cs)
EP (1) EP0667341B1 (cs)
JP (1) JPH07267926A (cs)
KR (1) KR950321212A (cs)
CN (1) CN1082948C (cs)
AT (1) ATE204864T1 (cs)
AU (1) AU693496B2 (cs)
CA (1) CA2142070A1 (cs)
CZ (1) CZ286681B6 (cs)
DE (2) DE4404183A1 (cs)
DK (1) DK0667341T3 (cs)
ES (1) ES2161789T3 (cs)
GR (1) GR3036839T3 (cs)
HU (1) HU215601B (cs)
NO (1) NO303685B1 (cs)
PL (1) PL179255B1 (cs)
PT (1) PT667341E (cs)
RU (1) RU2140412C1 (cs)
SK (1) SK281721B6 (cs)
TW (1) TW291476B (cs)
UA (1) UA43834C2 (cs)
ZA (1) ZA951059B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328352A1 (de) * 1993-08-24 1995-03-02 Hoechst Ag Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421495A1 (de) * 1994-06-20 1995-12-21 Merck Patent Gmbh Heterocyclyloxy-benzoylguanidine
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
DE4430861A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19608162A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19608161A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7620611B1 (en) * 1999-07-20 2009-11-17 Trilithic, Inc. Neural networks for ingress monitoring
ATE348808T1 (de) 2000-03-06 2007-01-15 Acadia Pharm Inc Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
EP1461339B1 (en) * 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CA2490397A1 (en) * 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
EP1693061A1 (en) * 2002-10-04 2006-08-23 Ucb, S.A. Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases
CN1816524B (zh) 2003-01-16 2012-06-27 阿卡蒂亚药品公司 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
BRPI0515015A (pt) * 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
EP2289879B1 (en) * 2004-09-27 2014-11-12 Acadia Pharmaceuticals Inc. Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
HUE037639T2 (hu) * 2007-09-21 2018-09-28 Acadia Pharm Inc Pimavanszerin együttes beadása más szerekkel
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE4117904A1 (de) * 1991-05-31 1992-12-03 Basf Ag Substituierte n-phenylpiperidine
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
ES2097409T3 (es) * 1992-09-22 1997-04-01 Hoechst Ag Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
EP0600371B1 (de) * 1992-12-02 1999-02-03 Hoechst Aktiengesellschaft Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
CZ286681B6 (en) 2000-06-14
CA2142070A1 (en) 1995-08-11
TW291476B (cs) 1996-11-21
ES2161789T3 (es) 2001-12-16
DE4404183A1 (de) 1995-08-17
ATE204864T1 (de) 2001-09-15
HU9500396D0 (en) 1995-03-28
US5461066A (en) 1995-10-24
HUT72306A (en) 1996-04-29
SK281721B6 (sk) 2001-07-10
PL307190A1 (en) 1995-08-21
NO950485L (no) 1995-08-11
JPH07267926A (ja) 1995-10-17
DE59509543D1 (de) 2001-10-04
EP0667341A1 (de) 1995-08-16
NO950485D0 (no) 1995-02-09
DK0667341T3 (da) 2001-10-22
AU693496B2 (en) 1998-07-02
CN1082948C (zh) 2002-04-17
PT667341E (pt) 2001-12-28
ZA951059B (en) 1995-10-13
PL179255B1 (pl) 2000-08-31
CN1112550A (zh) 1995-11-29
NO303685B1 (no) 1998-08-17
EP0667341B1 (de) 2001-08-29
HU215601B (hu) 1999-01-28
SK15795A3 (en) 1995-09-13
GR3036839T3 (en) 2002-01-31
RU2140412C1 (ru) 1999-10-27
AU1157195A (en) 1995-08-17
UA43834C2 (uk) 2002-01-15
KR950321212A (ko) 1995-12-20
RU95101843A (ru) 1997-03-10

Similar Documents

Publication Publication Date Title
CZ32795A3 (en) 4-amino-1-piperidylbenzoylguanidines, their use, process of their preparation, pharmaceutical compositions based thereon and process for preparing thereof
ES8302658A1 (es) "un procedimiento para la preparacion de nuevos derivados de piperidina"
PE74899A1 (es) Derivados de ergolina
PT93687A (pt) Processo para a preparacao de antagonistas de serotonina de tetra-hidrobenz,d}indole
ATE220675T1 (de) 4-oxozyklische harnstoffe mit antiarrhythmische und entfibrillatorische wirkung
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
DE3876402D1 (de) N-(2-alkyl-3-mercapto-1,5-dioxoalkyl)glycinamid-derivate und deren verwendung als kollagenase-inhibitoren.
ES2038124T3 (es) Procedimiento para preparar derivados piranicos.

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20030208